Europe Biosimilar Insulin Glargine and Lispro Market to Grow at Substantial Rate During Forecast Period
Ageing population and growing healthcare challenges
associated with diabetes to propel Europe biosimilar insulin glargine and
lispro market through 2024
According to
Tech Sci Research report, “Europe
Biosimilar Insulin Glargine and Lispro Market By End User, By Packaging, By
Country, Competition, Forecast & Opportunities, 2024”, Europe biosimilar insulin glargine and lispro market is anticipated
to grow at a formidable rate over the next 5 years on account of growing
expenditure on healthcare and increasing prevalence of obesity and diabetes in
the growing countries. Cost-effectiveness and drug efficacy are the major
factors for switching to biosimilar insulin due to the high cost of insulin
treatment. Thus, patient advocacy groups, healthcare professionals, and
policymakers, etc., are focusing on manufacturing of biosimilar insulin which is
expected to further drive Europe biosimilar insulin glargine and lispro market during
the forecast period. Germany is among the top
ten countries with maximum number of new cases of type 1 diabetes in children. However,
owing to the high competition among the major companies, the biosimilars will
face competition from new insulin products and can act as the major impediment
to the growth of Europe biosimilar insulin glargine and lispro market.
Europe
biosimilar insulin glargine and lispro market can be segmented based on end
user, packaging, and country. On the basis of packaging, the market can be
segmented into Vial, Pen and Cartridge. Of all, Vial segment dominated Europe
biosimilar insulin glargine and lispro market until 2018 and is expected to
maintain its dominance over the forecast period as well on account of growing
need for single dose aseptic sterile packaging to prevent the use of
preservatives coupled with its increased use in liquid pharmaceutical
applications which is boosting the
demand for vials, especially in applications like biosimilar insulin storage.
Sanofi,
Eli Lilly-Boehringer Ingelheim, Mylan-Biocon, Geropharm, Novo Nordisk,
Sandoz-Gan Lee, etc., are some of the leading players operating in Europe biosimilar
insulin glargine and lispro market. The companies operating in the market are
using strategies such as product launches, mergers and collaborations to boost
their share and expand their presence in the market.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4278
Customers
can also request for 10% free customization on this report.
“Europe biosimilar
insulin glargine and lispro market is anticipated to register a significant
growth during the next five years owing to the presence of the major players
such as Sanofi, Eli-Lilly, among others in the region. Moreover, growing
healthcare challenges associated with diabetes is further positively
influencing Europe biosimilar insulin glargine and lispro market.” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Europe Biosimilar Insulin Glargine &
Lispro Market By End User, By Packaging, By Country, Competition, Forecast
& Opportunities, 2024” has evaluated
the future growth potential of Europe biosimilar insulin glargine and lispro market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in Europe biosimilar insulin glargine and lispro market.
About TechSci Research
TechSci
Research is a leading global market research firm publishing premium market
research reports. Serving 700 global clients with more than 600 premium market
research studies, TechSci Research is serving clients across 11 different industrial
verticals. TechSci Research specializes in research-based consulting
assignments in high growth and emerging markets, leading technologies and niche
applications. Our workforce of more than 100 fulltime Analysts and Consultants
employing innovative research solutions and tracking global and country
specific high growth markets helps TechSci clients to lead rather than follow
market trends.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]